|
 |
||||||||
 |
ADVENTRX Pharmaceuticals is a development-stage specialty pharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates for the treatment of cancer. The Company seeks to improve the performance of existing drugs by addressing limitations associated principally with their safety and use. Our lead product candidates, ANX-530 (vinorelbine injectable emulsion), or Exelbine™, and ANX-514 (docetaxel lyophilized emulsion for injection), are novel emulsion formulations of currently marketed chemotherapy drugs. An interview with ADVENTRX Chief Executive Officer Brian M. Culley was featured in the October 19th issue of The Wall Street Transcript. |
|
